Details
Good News | Renfulikang has received the Clinical Trial Approval Notice for Class 1 Chemical Drug HW021199 Tablets.
Release time:
2021-05-08 11:38
Source:
Recently, HW021199 tablets—a Class 1 chemical drug for the treatment of idiopathic pulmonary fibrosis—jointly developed by Wuhan Fuli Kang Pharmaceutical Co., Ltd. and Hubei Institute of Biomedical Industry Technology Research Co., Ltd., received the “Notice of Approval for Clinical Trials” issued by the National Medical Products Administration. In accordance with the "Drug Administration Law of the People’s Republic of China" and relevant regulations, and after review to meet the requirements for drug registration, the authorities have approved the initiation of clinical trials.

Class 1 chemical drug HW021199 tablets,,,
Trending News
Corporate culture
Make drug launches safer and faster, and ensure the tree of life remains evergreen.
Learn more